Abstract
The antibacterial activity and clinical effects of pazufloxacin (PZFX), a new quinolone antimicrobial drug, were investigated. Minimum inhibitory concentrations (MICs) of PZFX were examined against 239 strains of 7 clinically isolated species at 106 cells/ml using plate dilution method. The drug showed 90% minimum inhibitory concentration (MIC90) levels of 0.2 μg/ml, 12.5 μg/ml, 0.1 μg/ml, 3.13 μg/ml, 0.1 μg/ml, 0.1μg/ml, 0.1μg/ml and 0.78 μg/ml against methicillin sensitive Staphylococcus aureus (MSSA), methicillin resistant S. aureus (MRSA), Escherichia coli, Serratia marcescens, Kiebsiella pneumoniae, Proteus mirabilis, Morganella morganii and Pseudomonas aeruginosa, respectively. PZFX was administered to 14 patients with respiratory infections diseases at a daily dose of 200-300 mg for 7-21 days, and the clinical effects were investigated. The drug was effective in 12, slightly effective in 1 and ineffective in 1. An efficacy rate was 85.7%. None of the patients had side effects or abnormalities in clinical laboratory tests.
